Ayelet Gonen
Yury I. Miller*- Department of Medicine, University of California, San Diego, San Diego, CA, United States
Esterification of cholesterol is a universal mechanism to store and transport large quantities of cholesterol between organs and tissues and to avoid toxicity of the excess of cellular cholesterol. Intended for transport and storage and thus to be inert, cholesteryl esters (CEs) reside in hydrophobic cores of circulating lipoproteins and intracellular lipid droplets. However, the inert identity of CEs is dramatically changed if cholesterol is esterified to a polyunsaturated fatty acid and subjected to oxidative modification. Post-synthetic, or epilipidomic, oxidative modifications of CEs are mediated by specialized enzymes, chief among them are lipoxygenases, and by free radical oxidation. The complex repertoire of oxidized CE (OxCE) products exhibit various, context-dependent biological activities, surveyed in this review. Oxidized fatty acyl chains in OxCE can be hydrolyzed and re-esterified, thus seeding oxidized moieties into phospholipids (PLs), with OxPLs having different from OxCEs biological activities. Technological advances in mass spectrometry and the development of new anti-OxCE antibodies make it possible to validate the presence and quantify the levels of OxCEs in human atherosclerotic lesions and plasma. The article discusses the prospects of measuring OxCE levels in plasma as a novel biomarker assay to evaluate risk of developing cardiovascular disease and efficacy of treatment.
Introduction
Cholesterol esterification is a mechanism the body uses to store and transfer cholesterol, while at the same time to avoid cellular toxicity of the excess of unesterified (often called free) cholesterol. However, oxidation of a cholesteryl ester (CE) drastically changes the part CE plays, from a subdued supporting actor to a contender for the leading role. The script, in other words, the specific physiological or pathological context, defines if oxidized CE (OxCE) plays a villain or the hero.
Unesterified cholesterol is an essential component of cellular membranes, where it plays both structural and signaling roles, the latter via regulation of lipid rafts and binding to many transmembrane proteins. In the nervous system, cholesterol is a major component of myelinated sheath of many nerve fibers. Cholesterol is also a precursor for biosynthesis of steroid hormones and bile acids. Thus, no wonder that cholesterol homeostasis is under tight control to ensure proper cellular and systemic functions. Dysregulation of cholesterol metabolism underlies many pathologies, from cardiovascular disease (CVD) to neurodegenerative disorders to cancer (1, 2). In homeostatic state, cellular cholesterol content is tightly controlled by balancing de novo synthesis, uptake of lipoproteins, export to extracellular milieu, and storage (2–4). The strategy for storage and transport of amphipathic cholesterol molecules is their esterification to fatty acids and tight packaging of the resulting hydrophobic CEs in the core of intracellular lipid droplets or circulating lipoproteins (Figure 1—Transport and Storage).
Figure 1 In search of CE identity—from inert storage to bioactivity and CVD biomarker. This diagram illustrates different biological processes that involve CEs, using examples described in text, and potential biomarker applications of detecting OxCEs in plasma and atherosclerotic plaques. Transport: Cholesteryl esters (CEs) together with triglycerides (TGs) populate the hydrophobic core of circulating lipoproteins, serving to deliver cholesterol and fatty acids to organs. Depicted is the low-density lipoprotein (LDL), a major CE-transporting lipoprotein in blood. Shown are representative structures (from top to bottom) of a TG, a CE with saturated fatty acyl [cholesteryl palmitate], and a CE with polyunsaturated fatty acyl (PUFA) [cholesteryl arachidonate], the latter is susceptible to oxidation. Storage: Intracellular lipid droplets predominantly store either CEs, like in macrophage foam cells in atherosclerotic lesions, or TGs, like in adipocytes. Oxidation: PUFA-CEs are the preferential substrate for 12/15-lipoxygenase (12/15-LO). Shown is cholesteryl 15(S)-HPETE, the product of 12/15LO-mediated oxidation of cholesteryl arachidonate, which in turn is oxidized to more complex products, like BEP-CE. Hydroperoxide, endoperoxide and aldehyde groups in OxCEs are reactive and can covalently modify proteins. Bioactivity: In one example of OxCE biological activity, BEP-CE and minimally modified LDL (mmLDL), which carry many OxCE molecules, activate an MD-2/TLR4/SYK pathway in macrophages, resulting in ROS generation, inflammatory cytokine secretion, and macropinocytosis-mediated LDL uptake and foam cell formation. OxCEs also activate endothelial cells, but their effects on vascular smooth muscle cells have not been studied. Biomarkers: Antibodies against OxCE-protein adducts stain human atherosclerotic lesions and recognize a fraction of ApoB and ApoA-I lipoproteins that carry OxCE in human plasma. In one example, an immunoassay measuring levels of OxCE-apoA lipoproteins detects reduced levels of this potential biomarker in subjects after treatment with atorvastatin compared to placebo. The artwork in this figure uses panels originally published in the Journal of Lipid Research. Gonen et al. A monoclonal antibody to assess oxidized cholesteryl esters associated with apoA-I and apoB-100 lipoproteins in human plasma. J Lipid Res 2019; 60:436-445. © The American Society for Biochemistry and Molecular Biology.
Inside the cells, after a threshold level in cellular cholesterol mass has been reached, excess cholesterol is esterified in the ER by the enzyme acyl CoA cholesterol acyltransferase (ACAT), and the newly synthesized CEs are stored in lipid droplets. To re-enter the cellular pathway, CE is hydrolyzed by neutral CE hydrolase (NCEH). Alternatively, lipid droplets are packaged into autophagosomes and fuse with lysosomes, where the CE is hydrolyzed by lysosomal acid lipase (LAL), generating unesterified cholesterol for delivery to cellular membranes or for export (5). Cellular CEs undergo a continual cycle of hydrolysis and re-esterification with a half-life of about 24 h (6, 7).
In circulation, lower density lipoproteins transport CEs from digestive organs to tissues, and high-density lipoprotein (HDL) returns excess cholesterol in the form of CE back to the liver. In brief, very-low-density lipoprotein (VLDL), packing triglycerides (TGs) and CEs, undergoes intravascular remodeling by shedding TGs and transitions into low-density lipoprotein (LDL), which is the most CE-rich lipoprotein in circulation. LDL is internalized by many cell types and thus delivers CEs to tissues. Serving the opposite function, HDL gathers excess of unesterified cholesterol from extrahepatic tissues in order to move it back to the liver. The HDL-associated enzyme lecithin-cholesterol acyltransferase (LCAT) catalyzes the esterification of free cholesterol with a fatty acyl transferred from the sn-2 position of phosphatidylcholine (PC), resulting in the formation of a CE. In addition, there is a bidirectional exchange of CEs and TGs between HDL and the apoB-containing lipoproteins VLDL and LDL, mediated by the CE transfer protein (CETP) in plasma (8, 9). In plasma of healthy human subjects, approximately 70% of cholesterol molecules are esterified and reside in lipoprotein cores (10, 11).
This abridged description of CE metabolism illustrates complex pathways involved in keeping CE locked away in hydrophobic cores of lipid droplets and lipoproteins for storage and safe passage through the body—that is until CE undergoes oxidation and becomes biologically active.
CE Oxidation
The acyl chain in a CE can be derived from a saturated, monounsaturated or polyunsaturated fatty acid (PUFA). The most common PUFA-CEs are cholesteryl linoleate [CE(18:2)], arachidonate [CE(20:4)], and docosahexaenoate [CE(22:6)]. The PUFAs are more susceptible to oxidation than cholesterol due to the presence of a weaker C-H bond at the bis-allylic position and will therefore be oxidized preferentially (12). The hydrogen atoms are easily abstracted from the bis-allylic positions of PUFAs to form a lipid radical - the first intermediate of enzymatic or non-enzymatic lipid peroxidation (13, 14). This article will be largely focused on the OxCEs with oxidized acyl chain and non-oxidized sterol, with a brief discussion of oxysteryl-containing OxCEs.
The enzyme 12/15-lipoxygenase (mouse 12/15-LO is highly homologous to human and rabbit 15-LO) differs from other PUFA-oxidizing enzymes like cyclooxygenases in that its preferential substrate is a CE and not a free fatty acids or a phospholipid (PL) (12, 15). In a test-tube reaction of LDL oxidation by rabbit 15-LO, even when the LDL particle is loaded with free linoleic acid, cholesteryl linoleate constitutes the major 15-LO substrate (15). However in vivo, 12/15-LO is an intracellular enzyme and LDL is an extracellular lipoprotein, so it was at first puzzling how CEs were oxidized by 12/15-LO. According to one suggested mechanism (16, 17), LDL binds to macrophage LDL receptor related protein-1 (LRP-1), which in turn induces 12/15-LO translocation from the cytosol to the cell membrane and mediates CE transport from LDL to the cell membrane, where it becomes oxidized by 12/15-LO, as well as the return of an OxCE to the LDL. It is unknown if any of lipid droplet-associated proteins can mediate a similar CE exchange and if CE oxidation can occur on the surface of intracellular lipid droplets.
Products of 12/15-LO–mediated CE oxidation are vulnerable to subsequent oxidation in free radical reactions, forming numerous and complex isoprostane OxCE products, with up to 6 oxygen atoms inserted in the molecule of cholesteryl arachidonate (18, 19). Among these polyoxygenated CE products, molecules with a bicyclic endoperoxide group (18–20), such as cholesteryl (9,11)-epidioxy-15-hydroperoxy-(5Z,13E)-prostadienoate (abbreviated as BEP-CE for the presence of bicyclic endoperoxide and hydroperoxide groups), have biological activities and can covalently modify proteins, including apolipoproteins, as discussed below. OxCEs can also decompose to produce highly reactive end products, like malondialdehyde (MDA) or 4-hydroxy-2-nonenal (4-HNE), which in turn covalently modify proteins and phosphatidylethanolamines (21, 22). These posttranslational modifications profoundly affect protein function.
In addition, intracellular OxCE hydrolysis and subsequent re-esterification of an oxidized fatty acyl chain can produce oxidized PL (OxPL) in the cell (12). In wild type but not 12/15-LO–deficient murine macrophages, radioisotope-labeled cholesteryl linoleate and cholesteryl arachidonate, either intracellular or as part of LDL, were oxidized by the macrophage 12/15-LO, and the oxidized fatty acyls in OxPL molecules originated from the OxCEs (12).
Esterification of Oxysterols
Oxysterols, derived from either enzymatic or non-enzymatic oxidation of cholesterol, are bioactive and play important regulatory roles (23, 24). Similar to esterification of cholesterol, esterification of oxysterols is mediated by ACAT in cells and LCAT in plasma, as well as by lysosomal phospholipase A2 (25, 26). Esterification of oxysterols in plasma shifts their distribution away from albumin to LDL and HDL (27), where approximately 95% of plasma esterified oxysterols are found (28–31).
OxCE Trafficking
Transport of OxCEs in circulation and their uptake by cells occur via the same pathways that traffic non-oxidized CEs. HDL carries 85% of total plasma CE hydroperoxides. While HDL and LDL carry approximately equal numbers of CE hydroperoxide molecules per particle, the CEs in HDL on a per lipid basis are over 20-fold “more oxidized” than those in LDL (32). Lipid peroxidation products in HDL are increased due to direct oxidation, transfer from LDL to HDL or by enzymatic re-esterification from OxPL by LCAT (9, 33, 34). CETP does not distinguish between CE and OxCE and mediates exchange of OxCE between HDL and LDL at the same rate as it transfers CE (9). Oxidized cholesteryl linoleate in which the fatty acyl moiety is oxidized to a hydroperoxide moves readily from HDL to hepatoma cells in serum-free medium (35), and the rate of SR-BI-mediated OxCE uptake by cells is approximately 9 times faster than that of non-oxidized CE and at least 40 times faster than the uptake of a whole HDL lipoprotein (36, 37). Because of the presence of hydrophilic, oxygen-containing groups in OxCE molecules, they become amphipathic and more mobile and presumably less confined to hydrophobic cores of lipoproteins or lipid droplets.
Biological Activity of OxCE
There is an important feature of OxCEs that sets them apart from other oxidized lipids—a combination of reactive and/or functional oxidation moieties in the fatty acyl chain, which we already discussed, with cholesterol. Unmodified cholesterol is a major regulatory molecule for many proteins. The cholesterol recognition/interaction amino acid consensus (CRAC) motif and its reverse version CARC are present in many transmembrane proteins and are essential for their function (38). In model binding experiments, cholesterol is often replaced with an acidic short-chain CE, cholesteryl hemisuccinate (39), suggesting that cholesterol esterification does not significantly affect its interaction with CRAC/CARC motifs. However, we have not seen direct experimental or modeling comparison of cholesterol and long-chain CE or OxCE binding to these domains. And we are unaware of studies of interaction between transmembrane proteins, like GPCRs, with OxCEs, which are bifunctional—carrying both unmodified cholesteryl and fatty acyl oxidation moieties.
In addition to transmembrane cholesterol-binding proteins, there are non-membrane proteins that have hydrophobic pockets where cholesterol docks, CETP and Niemann-Pick disease, type C2 protein (NPC2) being the most characterized proteins in this class. Another cholesterol-binding protein is MD-2 (40). MD-2 is the LPS-binding co-receptor for TLR4, an obligatory component for LPS-induced TLR4 activation and signaling. MD-2 has a β-cup fold structure composed of two antiparallel β sheets forming a hydrophobic pocket, with positively charged residues located near the opening rim of the pocket (41–43). Fatty acyl chains of LPS dock into the hydrophobic pocket, and negatively charged phosphate groups of LPS bind positively charged residues at the pocket opening. Likewise, in the molecule of cholesterol, a hydrocarbon chain together with the steroid form an elongated hydrophobic structure, which docks in the hydrophobic pocket of MD-2, and a hydroxyl group linked to the other side of the steroid stabilizes cholesterol at the positively charged entrance to the pocket. Test-tube experiments confirm that MD-2 binds cholesterol (40). Furthermore, cholesterol is found associated with the MD-2 immunoprecipitated from human plasma or from mouse atherosclerotic lesions (40). It is unlikely that unesterified cholesterol binding to MD-2 activates TLR4 because there is no moiety in the MD-2-bound cholesterol that would interact with TLR4, however, such a moiety is present in the cholesteryl esterified to a fatty acyl–CE. The hypothesis that an oxygenated fatty acyl chain in OxCE provides additional interaction surfaces, which, in combination with cholesteryl anchoring in the MD-2 hydrophobic pocket, provide sufficient interfaces for OxCE-induced MD-2-TLR4 binding, remains untested.
Although structural determinants are not yet elucidated, OxCE, and specifically BEP-CE, indeed induces MD-2 recruitment to TLR4 and TLR4 dimerization (44). Interestingly, MyD88, a TLR4 adaptor which mediates the bulk of LPS effects, minimally contributes to macrophage responses to minimally modified LDL (mmLDL), a major carrier of OxCE. Instead, spleen tyrosine kinase (SYK) has been identified as a kinase, which is recruited to TLR4 and mediates the majority of mmLDL- and OxCE-induced effects in macrophages (45–47). This dichotomy between LPS- and OxCE-mediated TLR4 responses attests, in addition to the pattern-recognition character of TLR4, to the TLR4 functional selectivity, similar to biased agonism of GPCRs (48).
The SYK-dependent activation of TLR4 by mmLDL and OxCE results in profound cytoskeleton changes in macrophages, including actin polymerization, cell spreading, membrane ruffling and macropinocytosis (44, 46, 49) (Figure 1—Bioactivity). Macropinocytosis is a robust mechanism of OxLDL, mmLDL, and native LDL uptake by macrophages and foam cell formation. In addition, mmLDL induces PLCγ, PKC and NOX2-dependent ROS production, which regulates expression of RANTES (CCL5), IL-1β, and IL-6 (45). NOX-2 also regulates mmLDL-induced expression of MCP-1 (CCL2), TNFα, MIP-2 (CXCL2), and MIP-1α (CCL3) (45). Tlr4−/− primary macrophages fail to respond to mmLDL or OxCE (44, 46, 49). Remarkably, in in vitro experiments, mmLDL and low-dose LPS, imitating subclinical endotoxemia observed in patients with the metabolic syndrome, synergize to produce higher levels of inflammatory cytokines. Although published data point to pro-inflammatory effects of OxCE, a more extensive literature on biological effects of OxPL describes both pro-and anti-inflammatory effects depending on the disease or pathological condition context (21). Thus, we cannot exclude the possibility of context-dependent, anti-inflammatory effects of OxCE, but this requires further research.
In contrast to the biological activity of fatty acyl-oxidized OxCE, esterification of oxysterols largely serves to curtail their biological activity (50). However, in neurons, ACAT-mediated esterification of 24(S)-hydroxycholesterol results in the formation of atypical lipid droplets and neurotoxicity (51). These findings suggest cell type and context dependent effects of esterification of oxysterols.
In addition to free lipid OxCE, cholesteryl fatty acyl hydroperoxides or endoperoxides (like in BEP-CE) can make covalent adducts with proteins and thus affect their function and/or produce novel protein-OxCE epitopes. For example, cholesteryl hydroperoxyoctadecadienoate (HPODE) forms covalent adducts with PDGF, TGFβ, and bFGF and inactivates them (52). In contrast, cholesteryl HPODE does not modify EGF (52), implying specificity of OxCE-protein modification, however, determinants of this specificity remain unclear. Similarly, remain unclear the exact mechanisms of cholesteryl HPODE and cholesteryl 9-oxononanoate (9-ON) induced activation of PKC and ERK1/2 in endothelial cells, which results in expression of fibronectin connecting segment-1 and enhanced adhesion of monocytes to endothelial cells (53). Cholesteryl 9-ON induces expression of both TFG-β and TGF-β receptor type I in human U937 promonocytic cells. This effect is mediated by ERK1/2 and potentially is involved in sustaining vascular remodeling in atherosclerosis (54). Cholesteryl HPODE, but not HPODE-containing OxPL, has been identified as an active component that induces PPARα-dependent expression of CD36 in human monocyte-derived macrophages (55). It is also possible that in the experimental systems employed in the above experiments, cholesteryl HPODE underwent further oxidative modifications, resulting in more complex products, which in turn evoked biological activity different from that of an initial hydroperoxide.
OxCE in Human Atherosclerotic Lesions
How relevant is the biological activity of OxCE to the pathogenesis of atherosclerosis? Definitive studies for OxCE are yet to be conducted but if any guide, recent work from Witztum’s group has demonstrated that constitutive expression of the single-chain E06 antibody, which neutralizes atherogenic effects of OxPL, in Ldlr−/− mice significantly reduces atherosclerosis and its co-morbidities (56, 57). In the absence of similar work targeting OxCE, we can only hypothesize that the substantial presence of OxCE in atherosclerotic lesions may have an atherogenic effect. Indeed, using advanced mass spectrometry techniques helped identify many OxCE species in human atherosclerotic lesions, estimating that, on average, 23% of cholesteryl linoleate, 16% of cholesteryl arachidonate and 12% of cholesteryl docosahexaenoate are oxidized (58). In a different study, OxCEs have accounted for 11 to 92% of the CE-PUFA pool in atherosclerotic plaques from different subjects (59). BEP-CE has been detected in human atherosclerotic lesions as well (44).
The studies cited in the previous paragraph identified free lipid OxCEs. It is technically challenging to construct a mass spectrometry method that would detect covalent OxCE adducts to proteins. However, these new epitopes can be detected with antibodies raised against the OxCE moiety independent of a protein, which has been covalently modified by this OxCE. For example, a monoclonal antibody raised against proteins modified with cholesteryl 9-ON has been shown to stain atherosclerotic lesions (60). Studies in our lab have produced a new monoclonal antibody that recognizes an OxCE epitope on modified proteins. To ensure the independence of an OxCE epitope recognition from the protein carrier, mice were immunized with OxCE-KLH and the antibody was selected against OxCE-BSA. The resulting antibody, AG23, bound OxCE-modified KLH, BSA, apoA-I, and a 6-amino acid peptide (61). The OxCE used for covalent modification of these proteins was a product of cholesteryl arachidonate oxidation with 2,2’-azobis (2,4-dimethylvaleronitrile) in an atmosphere of oxygen, which predominantly produced BEP-CE, but other complex oxidation products were present as well (44). The AG23 immunoreactivity was abundant in human carotid endarterectomy specimens, demonstrating the presence of OxCE epitopes in atherosclerotic lesions (Figure 1—Biomarkers) and suggesting relevance of OxCE to the pathogenesis of human CVD (61).
OxCE in Human Plasma as a Biomarker for CVD
As with detection of OxCE in atherosclerotic tissue, early studies employing biochemical and mass spectrometry techniques reported a wide range of CE hydroperoxides in human plasma, from 3 to 920 nmol/L (62, 63), with hydroperoxides of cholesteryl linoleate and cholesteryl arachidonate as the major oxidation products (32, 64–66). Plasma levels of CE hydroperoxides have been significantly increased on day 1 and peaked at day 5 after subarachnoid hemorrhage, returning to normal levels on days 7 and 9 (67). This temporal sequence correlates well with the known time course of cerebral vasospasm, which typically has its onset between 5 and 7 days after subarachnoid hemorrhage. Using a targeted lipidomic approach to quantify multiple classes of OxCE, Yin’s group tested plasma samples from 49 CVD patients and observed a significant elevation of multiple oxidation products of cholesteryl arachidonate and cholesteryl linoleate in plasma of patients with myocardial infarction compared to that of control and other CVD groups. These results suggest release of OxCEs from the raptured atherosclerotic plaque (68).
The AG23 mAb against OxCE described in the preceding section has been used to develop a new ELISA method to measure OxCE associated with apoA-I or apoB-100 lipoproteins in human plasma (61). This assay measures levels of lipoproteins that have at least one OxCE epitope. Measuring OxCE-apoB and OxCE-apoA in plasma samples from PROXI, a randomized parallel-arm double-blind placebo-controlled trial in which human subjects received placebo or a statin treatment for 16 weeks, we demonstrated that the OxCE-apoA levels were significantly lower in subjects treated with atorvastatin than in the placebo group, independent of the apoA-I levels (Figure 1—Biomarkers) (56). Testing larger cohorts of human subjects with different conditions and treatment regimens will determine if this particular OxCE assay will become a useful diagnostic and/or prognostic CVD biomarker.
Conclusions and Unresolved Questions
Biological activity and biomarker potential of OxCEs remain understudied. In part, this is due to a common perception of CEs as inherently inert intracellular “storage” and lipoprotein “transport” lipids, which is certainly the case for CEs with saturated fatty acyls. However, there exist mechanisms for oxidative modification of CEs with polyunsaturated fatty acyls, producing a multitude of OxCEs, which exhibit biological activity as free lipid and can covalently modify proteins. The unique feature of OxCEs is that they contain both an oxidized fatty acyl, which is often reactive and/or makes OxCEs less hydrophobic and thus more mobile, and the unmodified cholesteryl, which binds to and modulates function of many membrane and soluble proteins. In this article, we reviewed how cholesterol binding to MD-2 makes OxCE an agonist for TLR4, resulting in inflammatory and lipid accumulation responses in macrophages. Future studies will elucidate whether OxCE can interact with GPCRs, which potentially may have broad implications. More work is also needed to understand biological effects of esterified oxysterols, which seem to be tissue and pathology context dependent. The spectrum of proteins in plasma and in tissues that have OxCE covalent adducts remains unexplored, as remain poorly understood determinants of the OxCE specificity in covalent modification of proteins. The development of new antibodies that recognize OxCE-protein covalent complexes independent of a protein carrier will be instrumental in answering these questions. However, there remains a challenge of characterization of the exact chemical structure of OxCE-protein covalent adducts; where mass spectrometry methods are insufficient, co-crystallization of antibodies with their OxCE antigens may become a productive approach. Initial studies using OxCE-specific antibodies, as illustrated in this article, are promising but examination of larger cohorts of subjects with CVD and possibly other conditions are needed to fully evaluate the diagnostic and prognostic potential of OxCE as a new biomarker.
Author Contributions
AG and YM wrote this manuscript. All authors contributed to the article and approved the submitted version.
Funding
Work in authors’ laboratory is supported by the National Institute of Health Grants HL135737 and HL136275.
Conflict of Interest
AG and YM are inventors listed on patents and patent applications related to the topic of this article. YM is a scientific co-founder of Raft Pharmaceuticals LLC. The terms of this arrangement have been reviewed and approved by the University of California, San Diego, in accordance with its conflict of interest policies.
References
1. Luo J, Yang H, Song BL. Mechanisms and regulation of cholesterol homeostasis. Nat Rev Mol Cell Biol (2020) 21:225–45. doi: 10.1038/s41580-019-0190-7
2. Tabas I. Cholesterol in health and disease. J Clin Invest (2002) 110:583–90. doi: 10.1172/JCI0216381
3. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science (1986) 232:34–47. doi: 10.1126/science.3513311
4. Afonso MS, Machado RM, Lavrador MS, Quintao ECR, Moore KJ, Lottenberg AM. Molecular Pathways Underlying Cholesterol Homeostasis. Nutrients (2018) 10:760. doi: 10.3390/nu10060760
5. Gibson MS, Domingues N, Vieira OV. Lipid and Non-lipid Factors Affecting Macrophage Dysfunction and Inflammation in Atherosclerosis. Front Physiol (2018) 9:654. doi: 10.3389/fphys.2018.00654
6. Brown MS, Ho YK, Goldstein JL. The cholesteryl ester cycle in macrophage foam cells. Continual hydrolysis and re-esterification of cytoplasmic cholesteryl esters. J Biol Chem (1980) 255:9344–52.
7. Ghosh S, Zhao B, Bie J, Song J. Macrophage cholesteryl ester mobilization and atherosclerosis. Vascul Pharmacol (2010) 52:1–10. doi: 10.1016/j.vph.2009.10.002
8. Girotti AW. Translocation as a means of disseminating lipid hydroperoxide-induced oxidative damage and effector action. Free Radic Biol Med (2008) 44:956–68. doi: 10.1016/j.freeradbiomed.2007.12.004
9. Christison JK, Rye KA, Stocker R. Exchange of Oxidized Cholesteryl Linoleate between Ldl and Hdl Mediated by Cholesteryl Ester Transfer Protein. J Lipid Res (1995) 36:2017–26.
10. Bagheri B AA, Mokhtari H, Rasouli M. The Ratio of Unesterified/esterified Cholesterol is the Major Determinant of Atherogenicity of Lipoprotein Fractions. Med Arch (2018) 72:103–7. doi: 10.5455/medarh.2018.72.103-107
11. Schaefer EJ, Tsunoda F, Diffenderfer M, Polisecki E, Thai N, Asztalos B. The Measurement of Lipids, Lipoproteins, Apolipoproteins, Fatty Acids, and Sterols, and Next Generation Sequencing for the Diagnosis and Treatment of Lipid Disorders. Feingold KR, Anawalt B, Boyce A, Chrousos G, de Herder WW, Dungan K, Grossman A, Hershman JM, Hofland HJ, Kaltsas G, Koch C, Kopp P, Korbonits M, McLachlan R, Morley JE, New M, Purnell J, Singer F, Stratakis CA, Trence DL, Wilson DP, editors. South Dartmouth (MA: Endotext) (2000).
12. Hutchins PM, Murphy RC. Cholesteryl ester acyl oxidation and remodeling in murine macrophages: formation of oxidized phosphatidylcholine. J Lipid Res (2012) 53:1588–97. doi: 10.1194/jlr.M026799
13. Tyurina YY, Tyurin VA, Anthonymuthu T, Amoscato AA, Sparvero LJ, Nesterova AM, et al. Redox lipidomics technology: Looking for a needle in a haystack. Chem Phys Lipids (2019) 221:93–107. doi: 10.1016/j.chemphyslip.2019.03.012
14. Massey KA, Nicolaou A. Lipidomics of oxidized polyunsaturated fatty acids. Free Radic Biol Med (2013) 59:45–55. doi: 10.1016/j.freeradbiomed.2012.08.565
15. Belkner J, Stender H, Kuhn H. The rabbit 15-lipoxygenase preferentially oxygenates LDL cholesterol esters, and this reaction does not require vitamin E. J Biol Chem (1998) 273:23225–32. doi: 10.1074/jbc.273.36.23225
16. Takahashi Y, Zhu H, Xu W, Murakami T, Iwasaki T, Hattori H, et al. Selective uptake and efflux of cholesteryl linoleate in LDL by macrophages expressing 12/15-lipoxygenase. Biochem Biophys Res Commun (2005) 338:128–35. doi: 10.1016/j.bbrc.2005.07.182
17. Zhu H, Takahashi Y, Xu W, Kawajiri H, Murakami T, Yamamoto M, et al. Low density lipoprotein receptor-related protein-mediated membrane translocation of 12/15-lipoxygenase is required for oxidation of low density lipoprotein by macrophages. J Biol Chem (2003) 278:13350–5. doi: 10.1074/jbc.M212104200
18. Yin H, Havrilla CM, Morrow JD, Porter NA. Formation of isoprostane bicyclic endoperoxides from the autoxidation of cholesteryl arachidonate. J Am Chem Soc (2002) 124:7745–54. doi: 10.1021/ja0201092
19. Yin H, Morrow JD, Porter NA. Identification of a Novel Class of Endoperoxides from Arachidonate Autoxidation. J Biol Chem (2004) 279:3766–76. doi: 10.1074/jbc.M307137200
20. Harkewicz R, Hartvigsen K, Almazan F, Dennis EA, Witztum JL, Miller YI. Cholesteryl ester hydroperoxides are biologically active components of minimally oxidized low density lipoprotein. J Biol Chem (2008) 283:10241–51. doi: 10.1074/jbc.M709006200
21. Miller YI, Shyy JY. Context-Dependent Role of Oxidized Lipids and Lipoproteins in Inflammation. Trends Endocrinol Metab (2017) 28:143–52. doi: 10.1016/j.tem.2016.11.002
22. Matsuura E, Hughes GR, Khamashta MA. Oxidation of LDL and its clinical implication. Autoimmun Rev (2008) 7:558–66. doi: 10.1016/j.autrev.2008.04.018
23. Samadi A, Sabuncuoglu S, Samadi M, Isikhan SY, Chirumbolo S, Peana M, et al. A Comprehensive Review on Oxysterols and Related Diseases. Curr Med Chem (2020). doi: 10.2174/0929867327666200316142659
24. Griffiths WJ, Wang Y. An update on oxysterol biochemistry: New discoveries in lipidomics. Biochem Biophys Res Commun (2018) 504:617–22. doi: 10.1016/j.bbrc.2018.02.019
25. Rogers MA, Liu J, Song BL, Li BL, Chang CC, Chang TY. Acyl-CoA:cholesterol acyltransferases (ACATs/SOATs): Enzymes with multiple sterols as substrates and as activators. J Steroid Biochem Mol Biol (2015) 151:102–7. doi: 10.1016/j.jsbmb.2014.09.008
26. Abe A, Hiraoka M, Matsuzawa F, Aikawa SI, Niimura Y. Esterification of side-chain oxysterols by lysosomal phospholipase A2. Biochim Biophys Acta Mol Cell Biol Lipids (2020) 1865:158787. doi: 10.1016/j.bbalip.2020.158787
27. Lin CY, Morel DW. Esterification of oxysterols in human serum: effects on distribution and cellular uptake. J Lipid Res (1996) 37:168–78.
28. Bandaru VV, Haughey NJ. Quantitative detection of free 24S-hydroxycholesterol, and 27-hydroxycholesterol from human serum. BMC Neurosci (2014) 15:137. doi: 10.1186/s12868-014-0137-z
29. Dzeletovic S, Babiker A, Lund E, Diczfalusy U. Time course of oxysterol formation during in vitro oxidation of low density lipoprotein. Chem Phys Lipids (1995) 78:119–28. doi: 10.1016/0009-3084(95)02489-6
30. Burkard I, von Eckardstein A, Waeber G, Vollenweider P, Rentsch KM. Lipoprotein distribution and biological variation of 24S- and 27-hydroxycholesterol in healthy volunteers. Atherosclerosis (2007) 194:71–8. doi: 10.1016/j.atherosclerosis.2006.09.026
31. Babiker A, Diczfalusy U. Transport of side-chain oxidized oxysterols in the human circulation. Biochim Biophys Acta (1998) 1392:333–9. doi: 10.1016/S0005-2760(98)00047-2
32. Bowry VW, Stanley KK, Stocker R. High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. Proc Natl Acad Sci U S A (1992) 89:10316–20. doi: 10.1073/pnas.89.21.10316
33. Ito F, Ito T. High-Density Lipoprotein (HDL) Triglyceride and Oxidized HDL: New Lipid Biomarkers of Lipoprotein-Related Atherosclerotic Cardiovascular Disease. Antioxidants-Basel (2020) 9:362. doi: 10.3390/antiox9050362
34. Sattler W, Christison J, Stocker R. Cholesterylester hydroperoxide reducing activity associated with isolated high- and low-density lipoproteins. Free Radic Biol Med (1995) 18:421–9. doi: 10.1016/0891-5849(94)00170-O
35. Sattler W, Stocker R. Greater selective uptake by Hep G2 cells of high-density lipoprotein cholesteryl ester hydroperoxides than of unoxidized cholesteryl esters. Biochem J (1993) 294(Pt 3):771–8. doi: 10.1042/bj2940771
36. Fluiter K, Vietsch H, Biessen EA, Kostner GM, van Berkel TJ, Sattler W. Increased selective uptake in vivo and in vitro of oxidized cholesteryl esters from high-density lipoprotein by rat liver parenchymal cells. Biochem J (1996) 319(Pt 2):471–6. doi: 10.1042/bj3190471
37. Fluiter K, Sattler W, De Beer MC, Connell PM, van der Westhuyzen DR, van Berkel TJ. Scavenger receptor BI mediates the selective uptake of oxidized cholesterol esters by rat liver. J Biol Chem (1999) 274:8893–9. doi: 10.1074/jbc.274.13.8893
38. Fantini J, Epand RM, Barrantes FJ. Cholesterol-Recognition Motifs in Membrane Proteins. Adv Exp Med Biol (2019) 1135:3–25. doi: 10.1007/978-3-030-14265-0_1
39. Scalise M, Pochini L, Cosco J, Aloe E, Mazza T, Console L, et al. Interaction of Cholesterol With the Human SLC1A5 (ASCT2): Insights Into Structure/Function Relationships. Front Mol Biosci (2019) 6:110. doi: 10.3389/fmolb.2019.00110
40. Choi SH, Kim J, Gonen A, Viriyakosol S, Miller YI. MD-2 binds cholesterol. Biochem Biophys Res Commun (2016) 470:877–80. doi: 10.1016/j.bbrc.2016.01.126
41. Kim HM, Park BS, Kim JI, Kim SE, Lee J, Oh SC, et al. Crystal Structure of the TLR4-MD-2 Complex with Bound Endotoxin Antagonist Eritoran. Cell (2007) 130:906–17. doi: 10.1016/j.cell.2007.08.002
42. Park BS, Song DH, Kim HM, Choi BS, Lee H, Lee JO. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature (2009) 458:1191–5. doi: 10.1038/nature07830
43. Gruber A, Mancek M, Wagner H, Kirschning CJ, Jerala R. Structural model of MD-2 and functional role of its basic amino acid clusters involved in cellular lipopolysaccharide recognition. J Biol Chem (2004) 279:28475–82. doi: 10.1074/jbc.M400993200
44. Choi S-H, Yin H, Ravandi A, Armando A, Dumlao D, Kim J, et al. Polyoxygenated cholesterol ester hydroperoxide activates TLR4 and SYK dependent signaling in macrophages. PloS One (2013) 8:e83145. doi: 10.1371/journal.pone.0083145
45. Bae YS, Lee JH, Choi SH, Kim S, Almazan F, Witztum JL, et al. Macrophages Generate Reactive Oxygen Species in Response to Minimally Oxidized Low-Density Lipoprotein: Toll-Like Receptor 4- and Spleen Tyrosine Kinase-Dependent Activation of NADPH Oxidase 2. Circ Res (2009) 104:210–8. doi: 10.1161/CIRCRESAHA.108.181040
46. Choi S-H, Harkewicz R, Lee JH, Boullier A, Almazan F, Li AC, et al. Lipoprotein accumulation in macrophages via toll-like receptor-4-dependent fluid phase uptake. Circ Res (2009) 104:1355–63. doi: 10.1161/CIRCRESAHA.108.192880
47. Choi SH, Wiesner P, Almazan F, Kim J, Miller YI. Spleen Tyrosine Kinase Regulates AP-1 Dependent Transcriptional Response to Minimally Oxidized LDL. PloS One (2012) 7:e32378. doi: 10.1371/journal.pone.0032378
48. Anderson CA, Solari R, Pease JE. Biased agonism at chemokine receptors: obstacles or opportunities for drug discovery? J Leukoc Biol (2016) 99:901–9. doi: 10.1189/jlb.2MR0815-392R
49. Miller YI, Viriyakosol S, Binder CJ, Feramisco JR, Kirkland TN, Witztum JL. Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells. J Biol Chem (2003) 278:1561–8. doi: 10.1074/jbc.M209634200
50. Brown AJ, Sharpe LJ, Rogers MJ. Oxysterols: From physiological tuners to pharmacological opportunities. Br J Pharmacol (2020). doi: 10.1111/bph.15073
51. Takabe W, Urano Y, Vo DH, Shibuya K, Tanno M, Kitagishi H, et al. Esterification of 24S-OHC induces formation of atypical lipid droplet-like structures, leading to neuronal cell death. J Lipid Res (2016) 57:2005–14. doi: 10.1194/jlr.M068775
52. Van Heek M, Schmitt D, Toren P, Cathcart MK, DiCorleto PE. Cholesteryl hydroperoxyoctadecadienoate from oxidized low density lipoprotein inactivates platelet-derived growth factor. J Biol Chem (1998) 273:19405–10. doi: 10.1074/jbc.273.31.19405
53. Huber J, Boechzelt H, Karten B, Surboeck M, Bochkov VN, Binder BR, et al. Oxidized cholesteryl linoleates stimulate endothelial cells to bind monocytes via the extracellular signal-regulated kinase 1/2 pathway. Arterioscler Thromb Vasc Biol (2002) 22:581–6. doi: 10.1161/01.ATV.0000012782.59850.41
54. Gargiulo S, Gamba P, Sottero B, Biasi F, Chiarpotto E, Serviddio G, et al. The core-aldehyde 9-oxononanoyl cholesterol increases the level of transforming growth factor beta1-specific receptors on promonocytic U937 cell membranes. Aging Cell (2009) 8:77–87. doi: 10.1111/j.1474-9726.2009.00454.x
55. Jedidi I, Couturier M, Therond P, Gardes-Albert M, Legrand A, Barouki R, et al. Cholesteryl ester hydroperoxides increase macrophage CD36 gene expression via PPAR[alpha]. Biochem Biophys Res Commun (2006) 351:733–8. doi: 10.1016/j.bbrc.2006.10.122
56. Que X, Hung MY, Yeang C, Gonen A, Prohaska TA, Sun X, et al. Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice. Nature (2018) 558:301–6. doi: 10.1038/s41586-018-0198-8
57. Sun X, Seidman JS, Zhao P, Troutman TD, Spann NJ, Que X, et al. Neutralization of Oxidized Phospholipids Ameliorates Non-alcoholic Steatohepatitis. Cell Metab (2020) 31:189–206 e8. doi: 10.1016/j.cmet.2019.10.014
58. Hutchins PM, Moore EE, Murphy RC. Electrospray tandem mass spectrometry reveals extensive and non-specific oxidation of cholesterol esters in human peripheral vascular lesions. J Lipid Res (2011) 52:2070–83. doi: 10.1194/jlr.M019174
59. Ravandi A, Leibundgut G, Hung MY, Patel M, Hutchins PM, Murphy RC, et al. Release and capture of bioactive oxidized phospholipids and oxidized cholesteryl esters during percutaneous coronary and peripheral arterial interventions in humans. J Am Coll Cardiol (2014) 63:1961–71. doi: 10.1016/j.jacc.2014.01.055
60. Kawai Y, Saito A, Shibata N, Kobayashi M, Yamada S, Osawa T, et al. Covalent binding of oxidized cholesteryl esters to protein: implications for oxidative modification of low density lipoprotein and atherosclerosis. J Biol Chem (2003) 278:21040–9. doi: 10.1074/jbc.M212426200
61. Gonen A, Choi SH, Miu P, Agatisa-Boyle C, Acks D, Taylor AM, et al. A monoclonal antibody to assess oxidized cholesteryl esters associated with apoAI and apoB-100 lipoproteins in human plasma. J Lipid Res (2019) 60:436–45. doi: 10.1194/jlr.D090852
62. Yamamoto Y, Brodsky MH, Baker JC, Ames BN. Detection and characterization of lipid hydroperoxides at picomole levels by high-performance liquid chromatography. Analyt Biochem (1987) 160:7–13. doi: 10.1016/0003-2697(87)90606-3
63. Coghlan JG, Flitter WD, Holley AE, Norell M, Mitchell AG, Ilsley CD, et al. Detection of free radicals and cholesterol hydroperoxides in blood taken from the coronary sinus of man during percutaneous transluminal coronary angioplasty. Free Radic Res Commun (1991) 14:409–17. doi: 10.3109/10715769109093429
64. Polidori MC, Frei B, Cherubini A, Nelles G, Rordorf G, Keaney JF Jr., et al. Increased plasma levels of lipid hydroperoxides in patients with ischemic stroke. Free Radical Biol Med (1998) 25:561–7. doi: 10.1016/S0891-5849(98)00085-9
65. Yamamoto Y, Mashima R. Presence of regio-isomeric cholesteryl linoleate hydroperoxides and hydroxides in plasma from healthy humans as evidence of free radical-mediated lipid peroxidation in vivo. Redox Rep (2000) 5:162–3. doi: 10.1179/135100000101535582
66. Mashima R, Onodera K, Yamamoto Y. Regioisomeric distribution of cholesteryl linoleate hydroperoxides and hydroxides in plasma from healthy humans provides evidence for free radical-mediated lipid peroxidation in vivo. J Lipid Res (2000) 41:109–15.
67. Polidori MC, Frei B, Rordorf G, Ogilvy CS, Koroshetz WJ, Beal MF. Increased levels of plasma cholesteryl ester hydroperoxides in patients with subarachnoid hemorrhage. Free Radical Biol Med (1997) 23:762–7. doi: 10.1016/S0891-5849(97)00053-1
Keywords: cholesteryl ester, oxidized, macrophage, atherosclerosis, cardiovascular disease, biomarker, inflammation, toll-like receptor 4
Citation: Gonen A and Miller YI (2020) From Inert Storage to Biological Activity—In Search of Identity for Oxidized Cholesteryl Esters. Front. Endocrinol. 11:602252. doi: 10.3389/fendo.2020.602252
Received: 02 September 2020; Accepted: 23 October 2020;
Published: 20 November 2020.
Edited by:
Maria Fedorova, Leipzig University, GermanyReviewed by:
Huiyong Yin, Chinese Academy of Sciences (CAS), ChinaNorbert Leitinger, University of Virginia, United States
Copyright © 2020 Gonen and Miller. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yury I. Miller, eXVtaWxsZXJAaGVhbHRoLnVjc2QuZWR1